Stockreport

X4 Pharmaceuticals Receives Positive Opinion from the EMA CHMP Recommending Approval of Mavorixafor in the EU for WHIM Syndrome [Yahoo! Finance]

X4 Pharmaceuticals, Inc.  (XFOR) 
Last x4 pharmaceuticals, inc. earnings: 3/12 07:30 am Check Earnings Report
PDF - Potential First and Only Therapy in the EU for Ultra-Rare Immune Disorder - BOSTON, Feb. 27, 2026 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company f [Read more]